Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. Purpose: The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity. In addition to the well-recognized manifestations of cannabinoid hyperemesis, cannabinoid mechanisms result in human and animal models of gastrointestinal and colonic dysmotility. Decreased enteric FAAH activity is associated with colonic inertia in slow transit constipation and, conversely, the orphan G protein-coupled receptor, GPR55, is overexpressed in streptozotocin-induced gastroparesis, suggesting it is involved in inhibition of antral motility. Experimental therapies in gastrointestinal motility and functional disorders are focused predominantly on pain relief mediated through cannabinoid 2 receptors or inhibition of DAGLα to normalize colonic transit. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.

Original languageEnglish (US)
JournalNeurogastroenterology and Motility
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Gastrointestinal Motility
Cannabinoids
Clinical Pharmacology
Therapeutic Uses
Constipation
Cannabinoid Receptor Agonists
Gastroparesis
Cannabinoid Receptors
Investigational Therapies
Dronabinol
Gastric Emptying
Gastroenterology
Cannabis
Streptozocin
G-Protein-Coupled Receptors
Animal Models
Pharmacology
Pressure
Pain

Keywords

  • 2-AG
  • Anandamide
  • DAGL
  • FAAH

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology

Cite this

@article{6df8b2795b194473ab1e255f2ea44e33,
title = "Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans",
abstract = "Background: Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. Purpose: The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity. In addition to the well-recognized manifestations of cannabinoid hyperemesis, cannabinoid mechanisms result in human and animal models of gastrointestinal and colonic dysmotility. Decreased enteric FAAH activity is associated with colonic inertia in slow transit constipation and, conversely, the orphan G protein-coupled receptor, GPR55, is overexpressed in streptozotocin-induced gastroparesis, suggesting it is involved in inhibition of antral motility. Experimental therapies in gastrointestinal motility and functional disorders are focused predominantly on pain relief mediated through cannabinoid 2 receptors or inhibition of DAGLα to normalize colonic transit. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.",
keywords = "2-AG, Anandamide, DAGL, FAAH",
author = "Michael Camilleri",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/nmo.13370",
language = "English (US)",
journal = "Neurogastroenterology and Motility",
issn = "1350-1925",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cannabinoids and gastrointestinal motility

T2 - Pharmacology, clinical effects, and potential therapeutics in humans

AU - Camilleri, Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. Purpose: The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity. In addition to the well-recognized manifestations of cannabinoid hyperemesis, cannabinoid mechanisms result in human and animal models of gastrointestinal and colonic dysmotility. Decreased enteric FAAH activity is associated with colonic inertia in slow transit constipation and, conversely, the orphan G protein-coupled receptor, GPR55, is overexpressed in streptozotocin-induced gastroparesis, suggesting it is involved in inhibition of antral motility. Experimental therapies in gastrointestinal motility and functional disorders are focused predominantly on pain relief mediated through cannabinoid 2 receptors or inhibition of DAGLα to normalize colonic transit. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.

AB - Background: Cannabinoid agents and cannabis are frequently used for relief of diverse gastrointestinal symptoms. Purpose: The objective of this article is to increase the awareness of gastroenterologists to the effects of cannabinoids on gastrointestinal motility, as gastroenterologists are likely to encounter patients who are taking cannabinoids, or those with dysmotility that may be associated with cannabinoid mechanisms. The non-selective cannabinoid agonist, dronabinol, retards gastric emptying and inhibits colonic tone and phasic pressure activity. In addition to the well-recognized manifestations of cannabinoid hyperemesis, cannabinoid mechanisms result in human and animal models of gastrointestinal and colonic dysmotility. Decreased enteric FAAH activity is associated with colonic inertia in slow transit constipation and, conversely, the orphan G protein-coupled receptor, GPR55, is overexpressed in streptozotocin-induced gastroparesis, suggesting it is involved in inhibition of antral motility. Experimental therapies in gastrointestinal motility and functional disorders are focused predominantly on pain relief mediated through cannabinoid 2 receptors or inhibition of DAGLα to normalize colonic transit. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.

KW - 2-AG

KW - Anandamide

KW - DAGL

KW - FAAH

UR - http://www.scopus.com/inward/record.url?scp=85046786594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046786594&partnerID=8YFLogxK

U2 - 10.1111/nmo.13370

DO - 10.1111/nmo.13370

M3 - Article

C2 - 29745439

AN - SCOPUS:85046786594

JO - Neurogastroenterology and Motility

JF - Neurogastroenterology and Motility

SN - 1350-1925

ER -